SOCASA | Changes in Drug Manufacturing and Dispensing Show Positive Effects
post-template-default,single,single-post,postid-1428,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.1,vc_responsive

Changes in Drug Manufacturing and Dispensing Show Positive Effects

 There is some good news on the prescription drug abuse prevention front. A study published in JAMA Internal Medicine shows that after 2010, when oxycodone manufacturers made it crush-resistant in order to deter abuse,  overdose rates fell substantially. The dangers of opioid painkillers such as oxycodone (better known by the brand name OxyContin) are that it can be misused by the person its prescribed for, and it can also be shared or sold illegally to others. At the same time as the crush-resistant form of oxycodone was released, there was also a drop in the levels of prescribing the medication, as healthcare practitioners became more aware of the potential for abuse.

The researchers concluded that “Our results have significant implications for policymakers and health care professionals grappling with the epidemic of opioid abuse and overdose. Changes imposed through regulatory mandates or voluntary company actions may be a viable approach to stemming prescription abuse.”

 Read more.